



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known:	
				Application Number	10/534650
				Filing Date	May 12, 2005
				First Named Inventor	Darren Mckerrecher
				Art Unit	1625
				Examiner Name	Morris, Patricia L.
Sheet	1	of	1	Attorney Docket Number	ASZD-P01-897

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CM1	Mckerrecher et al., "Identification of Orally Bioavailable Small Molecule Activators of Glucokinase," 12th SCI-RSC Medicinal Chemistry Symposium, Cambridge, UK, 7-10 September 2003	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	10/24/06
-----------------------	--	--------------------	----------





PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/534650
				Filing Date	May 12, 2005
				First Named Inventor	Darren McKeircher
				Art Unit	1615
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	ASZD-P01-897

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number-Kind Code ² (if known)				
BA	WO-00/58293-A1	10-05-2000	F. Hoffmann-La Roche AG			
	BB	WO-01/20327-A1	03-22-2001	AstraZeneca AB		
	BC	WO-01/44216-A1	06-21-2001	F. Hoffman-La Roche AG		
	BD	WO-01/83465-A2	11-08-2001	F. Hoffman-La Roche AG		
	BE	WO-01/83478-A2	11-08-2001	F. Hoffman-La Roche AG		
	BF	WO-01/85706-A1	11-15-2001	F. Hoffman-La Roche AG		
	BG	WO-01/85707-A1	11-15-2001	F. Hoffman-La Roche AG		
	BH	WO-02/08209-A1	01-31-2002	F. Hoffman-La Roche AG		
	BI	WO-02/14312-A1	02-21-2002	F. Hoffman-La Roche AG		
	BJ	WO-02/46173-A1	06-13-2002	F. Hoffman-La Roche AG		
	BK	WO-02/48106-A2	06-20-2002	F. Hoffman-La Roche AG		
	BL	WO-03/000262-A1	01-03-2003	AstraZeneca AB		
	BM	WO-03/000267-A1	01-03-2003	AstraZeneca AB		
	BN	WO-03/015774-A1	02-27-2003	AstraZeneca AB		
	BO	WO-03/022856-A1	03-20-2003	Pharmacia & Upjohn Company		
	BP	WO-03/047626-A1	06-12-2003	Novo Nordisk A/S		
	BQ	WO-03/055482-A1	07-10-2003	Novo Nordisk A/S		
	BR	WO-03/080585-A1	10-02-2003	Banyu Pharmaceutical Co., Ltd.		
	BS	WO-03/095438-A1	11-20-2003	F. Hoffman-La Roche AG		
	BT	WO-03/097824-A1	11-27-2003	Banyu Pharmaceutical Co., Ltd.		
	BU	WO-04/002481-A1	01-08-2004	Novo Nordisk A/S		
	BV	WO-04/045614-A1	06-03-2004	AstraZeneca AB		
	BW	WO-04/046139-A1	06-03-2004	AstraZeneca AB		
	BX	WO-04/050645-A1	06-17-2004	Novartis AG		
	BY	WO-04/052869-A1	06-24-2004	F. Hoffman-La Roche AG		
	BZ	WO-04/063179-A1	07-29-2004	Eli Lilly and Company		
	BA1	WO-04/063194-A1	07-29-2004	Eli Lilly and Company		
	BB1	WO-04/072031-A2	08-26-2004	Osi Pharmaceuticals, Inc.		
	BC1	WO-04/072066-A1	08-26-2004	Osi Pharmaceuticals, Inc.		
	BD1	WO-04/076420-A1	09-10-2004	Banyu Pharmaceutical Co., Ltd.		
	BE1	WO-04/081001-A1	09-23-2004	Banyu Pharmaceutical Co., Ltd.		
	BF1	WO-05/044801-A1	05-19-2005	AstraZeneca AB		
	BG1	WO-05/049019-A1	06-02-2005	Novo Nordisk A/S		
	BH1	WO-05/054200-A1	06-16-2005	AstraZeneca AB		
	BI1	WO-05/054233-A1	06-16-2005	AstraZeneca AB		
	BJ1	WO-05/056530-A1	06-23-2005	AstraZeneca AB		

Examiner Signature		Date Considered	10/21/06
-----------------------	--	--------------------	----------

Substitute for form 1448A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/534650		
		Filing Date	May 12, 2005.		
		First Named Inventor	Darren McKerrecher		
		Art Unit	1615		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	3	Attorney Docket Number	ASZD-P01-897

BK1	EP-1336607-A1	08-20-2003	Novo Nordisk A/S		
BL1	GB-2385328-A	08-20-2003	F. Hoffman-La Roche AG		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CA	Alvarez et al., "Expression of the Glucagon-Like Peptide-1 Receptor Gene in Rat Brain," Journal of Neurochemistry 66(3):920-927 (1998)		
	CB	Alvarez et al., "Evidence that Glucokinase Regulatory Protein is Expressed and Interacts with Glucokinase in Rat Brain," Journal of Neurochemistry 80:45-53 (2002)		
	CC	Bell et al., "Glucokinase Mutations, Insulin Secretion, and Diabetes Mellitus," Annu. Rev. Physiol. 58:171-186 (1996)		
	CD	Brocklehurst et al., "Stimulation of Hepatocyte Glucose Metabolism by Novel Small Molecule Glucokinase Activators," Diabetes 53:535-541 (2004)		
	CE	Caro et al., "Liver Glucokinase: Decreased Activity in Patients with Type II Diabetes," Horm. Metab. Res. 27:19-22 (1995)		
	CF	Christesen et al., "The Second Activating Glucokinase Mutation (A456V) Implications for Glucose Homeostasis and Diabetes Therapy," Diabetes 51:1240-1246 (2002)		
	CG	Corbett, "Track 3 - Mastering Medicinal Chemistry: Applying Organic Chemistry to Biological Problems, Success Stories in Medicinal Chemistry," Molecular Medicine Tri-Conference, Moscone West Convention Center, San Francisco California, 3/26/05 - 11:00-11:30 Glucokinase Activators: Discovery of Novel, Orally Active Glucose Lowering Agents, March 24-26, 2004		
	CH	DeFronzo, "The Triumvirate: β -Cell, Muscle, Liver - A Collusion Responsible for NIDDM," Diabetes 37:667-687 (1988)		
	CI	Desai et al., "Phenotypic correction of Diabetic Mice by Adenovirus-Mediated Glucokinase Expression," Diabetes 50:2287-2295 (2001)		
	CJ	Ferre et al., "Correction of Diabetic Alterations by Glucokinase," Proc. Natl. Acad. Sci. USA 93:7225-7230 (1996)		
	CK	Froguel et al., "Familial Hyperglycemia Due to Mutations in Glucokinase - Definition of a Subtype of Diabetes Mellitus," The New England Journal of Medicine 328(10):697-702 (1993)		
	CL	Fujimoto et al., "Administration of D-Glucosamine into the Third Cerebroventricle Induced Feeding Accompanied by Hyperglycemia in Rats," Life Sciences 37(26):2475-2482 (1985)		
	CM	Glaser et al., "Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation," The New England Journal of Medicine 338(4):226-230 (1998)		
	CN	Grimsby et al., "Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy," Science 301:370-373 (2003)		
	CO	Grimsby, "Glucokinase Activators - Potential Treatment for Type 2 Diabetes," Roche - SMI Diabetes London UK pgs. 28-29 (2002)		
	CP	Kurata et al., "Structural Evaluation of Glucose Analogues on Feeding Elicitation in Rat," Metabolism 38(1):46-51 (1989)		

Examiner Signature		Date Considered	10/24/06
--------------------	--	-----------------	----------


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/534650
				Filing Date	May 12, 2005
				First Named Inventor	Darren McKerrecher
				Art Unit	1615
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	ASZD-P01-897

<input checked="" type="checkbox"/>	CQ	Kurata et al., "D-Glucose Suppression of Eating After Intra-Third Ventricle Infusion in Rat," Physiology & Behavior 37:615-620 (1986)	
<input checked="" type="checkbox"/>	CR	Levin, "Glucosensing Neurons do More Than Just Sense Glucose," International Journal of Obesity 25(5):S68-S72 (2001)	
<input type="checkbox"/>	CS	Levin et al., "Differential Effects of Diet and Obesity on High and Low Affinity Sulfonylurea Binding Sites in the Rat Brain," Brain Research 739:293-300 (1996)	
<input type="checkbox"/>	CT	Levin et al., "In vivo and In vitro Regulation of [³ H] Glyburide Binding to Brain Sulfonylurea Receptors in Obesity-Prone and Resistant Rats by Glucose," Brain Research 776:146-153 (1997)	
<input type="checkbox"/>	CU	Levin et al., "Brain Glucose Sensing and body Energy Homeostasis: Role in Obesity and Diabetes," A. J. of Physiology 276:R1223-R1231 (1999)	
<input type="checkbox"/>	CV	Levin et al., "Reduced Glucose-Induced Neuronal Activation in the Hypothalamus of Diet-Induced Obese Rats," Brain Research 808:317-319 (1998)	
<input type="checkbox"/>	CW	Lynch et al., "Localization of Glucokinase Gene Expression in the Rat Brain," Diabetes 49:693-700 (2000)	
<input type="checkbox"/>	CX	McKerrecher et al., "Discovery, Synthesis and Biological Evaluation of Novel Glucokinase Activators," Bioorganic & Medicinal chemistry Letters 15:2103-2106 (2005)	
<input type="checkbox"/>	CY	Mobbs et al., "Brain Glucose-Sensing Mechanisms: Ubiquitous Silencing by Aglycemia vs. Hypothalamic Neuroendocrine Responses," Am. J. Physiol. Endocrinol. Metab. 281:E649-E654 (2001)	
<input type="checkbox"/>	CZ	Moore et al., "Acute Fructose Administration Improves Oral Glucose Tolerance in Adults with Type 2 Diabetes," Diabetes Care 24(11):1882-1887 (2001)	
<input type="checkbox"/>	CA1	Printz et al., "Mammalian Glucokinase," Annu. Rev. Nutr. 13:463-496 (1993)	
<input type="checkbox"/>	CB1	Qian-Cutrone et al., "Glucolipin A and B, Two New Glucokinase Activators Produced by Streptomyces purpurogeniscleroticus and Nocardia vaccinii," The Journal of Antibiotics 52(3):245-255 (1999)	
<input type="checkbox"/>	CC1	Roncero et al., "Functional Glucokinase Isoforms are Expressed in Rat Brain," Journal of Neurochemistry 74(5):1848-1857 (2000)	
<input type="checkbox"/>	CD1	Rowe et al., "Potassium Channel Dysfunction in Hypothalamic Glucose-Receptive Neurones of Obese Zucker Rats," Journal of Physiology 497(2):365-377 (1996)	
<input type="checkbox"/>	CE1	Schuit et al., "Perspectives in Diabetes - Glucose Sensing in Pancreatic β -Cells - A Model for the Study of Other Glucose-Regulated Cells in Gut, Pancreas, and Hypothalamus," Diabetes 50:1-11 (2001)	
<input type="checkbox"/>	CF1	Seoane et al., "Glucokinase Overexpression Restores Glucose Utilization and Storage in Cultured Hepatocytes from Male Zucker Diabetic Fatty Rats," The Journal of Biological Chemistry 274(45):31833-31838 (1999)	
<input type="checkbox"/>	CG1	Shiota et al., "Glucokinase Gene Locus Transgenic Mice are Resistant to the Development of Obesity-Induced Type 2 Diabetes," Diabetes 50:622-629 (2001)	
<input type="checkbox"/>	CH1	Spannwick et al., "Insulin Activates ATP-Sensitive K ⁺ Channels in Hypothalamic Neurons of Lean, but Not Obese Rats," Nature Neuroscience 3(8):757-758 (2000)	
<input type="checkbox"/>	CI1	Spannwick et al., "Leptin Inhibits Hypothalamic Neurons by Activation of ATP-Sensitive Potassium Channels," Nature 390:521-525 (1997)	
<input type="checkbox"/>	CJ1	Velho et al., "Impaired Hepatic Glycogen Synthesis in Glucokinase-Deficient (MODY-2) Subjects," J. Clin. Invest. 98:1755-1761 (1996)	
<input checked="" type="checkbox"/>	CK1	Yang et al., "Hypothalamic Glucose Sensor - Similarities to and Differences from Pancreatic β -Cell Mechanisms," Diabetes 48:1763-1772 (1999)	
<input type="checkbox"/>	CL1	Carroll et al., "Stress, Signalling and Control, Biochemical Society Meeting 679 2-4 July 2003	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	10/24/16
--------------------	---	-----------------	----------

10/534650

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	May 12, 2005
				First Named Inventor	Darren Mc Kerrecher
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	ASZD-P01-897

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear


FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO-01/44216	06-21-2001			

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Search Report for PCT/GB9903/004949 (2/26/04)	

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	10/24/06
--------------------	---	-----------------	----------